We propose a general pharmacokinetic-pharmacodynamic model that integrates the rhythmic fluctuation of hormone secretion for the description of the hormone-lowering effect of a drug. The mathematical model takes into account the variation in response observed after administration of a placebo and the drug. It is assumed that the change with time in the physiological response during the placebo period results from fluctuations in the concentration of hypothetical endogenous molecules. The mathematical formulation for predicting the response after drug intake is derived assuming competitive interaction of these “molecules” with the active species for binding to receptors. The suggested “fluctuation model” was implemented in order to describe the time course of the prolactin (PRL) plasma level after administration of two oral doses (2.5 and 5.0 mg) of the dopaminomimetic compound DCN 203–922 (DCN) to 9 healthy male subjects. Its perform ance was compared with that of conventional modeling approaches, in which the circadian changes after placebo are neglected and the hormone baseline is assumed to be constant. The new model provided a better description of the time course of PRL in most subjects. It was used for prediction of the amplitude and duration of the PRL suppressant effect after single and chronic administration of DCN at various dosage regimens as well as after changes in drug absorption.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
E. van Cauter and S. Retetoff. Multifactorial control of the 24-hour secretory profiles of pituitary hormones.J. Endocrinol. Invest. 8:381–391 (1985).
W. A. Colburn and D. M. Gibson. Endogenous agonists and pharmacokinetic/pharmacodynamic modeling of baseline effects. In P. D. Kroboth, R. B. Smith, and R. P. Juhl (eds.),Pharmacokinetics and Pharmacodynamics: Vol. 2 Current Problems, Potential Solutions, Harvey Whitney, Cincinnati, OH, 1988, pp. 167–184.
N. H. G. Holford and L. B. Sheiner. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models.Clin. Pharmacokin. 6:429–453 (1981).
L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine.Clin. Pharmacol. Ther. 25:358–371 (1979).
J. R. Keichel, J. L. Steimer, and A. Frydman. La modélisation pharmacocinétique et pharmacodynamique. In G. Strauch and A. Spriet (eds.),Pharmacologie Clinique: Actualités et Perspectives, Colloque INSERM, Paris, Vol. 156, 1987, pp. 91–118.
B. Oosterhuis and C. J. Van Boxtel. Kinetics of drug effects in man.Ther. Drug Monit. 10:121–132 (1988).
D. R. Stanski, R. J. Hundson, T. D. Homer, L. J. Saidman, and E. Meathe, Pharmacodynamic modeling of thiopental anesthesia.J. Pharmacokin. Biopharm. 12:223–240 (1984).
R. Platzer, R. L. Galeazzi, W. Niederberger, and J. Rosenthaler. Simultaneous modeling of bopindolol kinetics and dynamics.Clin. Pharmacol. Ther. 36:5–13 (1984).
W. A. Colburn, R. K. Brazzell, and A. A. Holazo. Verapamil pharmacodynamics after intravenous and oral dosing: Theoretic consideration.J. Clin. Pharmacol. 26:71–73 (1986).
J. Grevel, J. Brownell, J.-L. Steimer, R. C. Gaillard, and J. Rosenthaler. Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP 201–403 by an integrated pharmacokinetic-pharmacodynamic model.Br. J. Clin. Pharmacol. 22:1–13 (1986).
T. J. O’Leary and P. Abbrecht. Predicting oral anticoagulant response using pharmacodynamic model.Ann. Biomed. Eng. 9:199–216 (1981).
D. S. Cooper, E. C. Ridgway, B. Kliman, R. N. Kjellberg, and F. Maloof. Metabolic clearance and productions rates of prolactin in man.J. Clin. Invest. 64:1669–1680 (1979).
C. A. DeBoor.Practical Guide to Splines, Springer-Verlag, New York, 1978.
D. P. Vaughan and M. Dennis. Mathematical basis of point-area deconvolution, method for determingin vivo input functions.J. Pharm. Sci. 67:663–665 (1978).
J. Vilain, P. Francheteau, and J.-L. Steimer. Phacin: Un logiciel pour la modélisation compartimentale et l’estimation de paramétres pharmacocinétiques. In F. Grémy (ed.),Journées d’Informatique Médicale de Montpellier, Sauramps Medical, Montpellier, France, 1988, pp. 124–132.
L. B. Sheiner. Analysis of pharmacokinetic data using parametric models. I. Regression models.J. Pharmacokin. Biopharm. 12:93–117 (1984).
L. B. Sheiner. Analysis of pharmacokinetic data using parametric models. II. Point estimates of an individual’s parameters.J. Pharmacokin. Biopharm. 13:514–540 (1985).
J.-L. Steimer, J.-P. Jais, P. Francheteau, and Y. Plusquellec. Pharmacokinetic modelling with multi-response individual data: Case studies and discussion.Biomed. Meas. Infor. Contr. 2:147–160 (1988).
E. van Cauter, M. L’Hermite, G. Copinschi, S. Retetoff, D. Desir, and C. Robyn. Quantitative analysis of spontaneous variations of plasma prolactin in normal man.Am. J. Physiol. 241:E355–363 (1981).
E. van Cauter. The analysis of 24-hour hormonal profiles. In D. Rodbard and G. Forti (eds.),Computers in Endocrinology, Serono Symposia Publications, Vol. 14, Raven Press, New York, 1984, pp. 313–324.
SAS, Statistical Analysis System (Version 5). SAS Institute, Box 8000, Cary, NC 27511, 1985.
J. F. Sassin, A. G. Frantz, E. D. Weitzman, and S. Kapen. Human prolactin: 24-hour pattern with increased release during sleep.Science 177:1205–1207 (1972).
A. G. Frantz. Rhythms in prolactin secretion. In D. T. Krieger (ed.),Endocrine Rhythms, Raven Press, New York, 1979, pp. 175–186.
H. C. Porchet, N. L. Benowitz, and L. B. Sheiner. Pharmacodynamic model of tolerance: Application to nicotine.J. Pharmacol. Exp. Ther. 244:231–236 (1988).
W. R. Gillespie, P. Veng-Pedersen, E. J. Antal, and J. P. Phillips. A system approach to pharmacodynamics II: Glyburide pharmacodynamics and estimation of optimal drug delivery.J. Pharm. Sci. 77:48–55 (1988).
J. Unadkat, R. J. Hudson, L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with non-parametric kinetic and dynamic models.Clin. Pharmacol. Ther. 40:86–93 (1986).
F. O’Sullivan and J. O’Sullivan. Deconvolution of episodic hormone data: An analysis of the role of the season on the onset of puberty in cows.Biometrics 44:339–353 (1988).
P. J. Diggle and S. C. Zeger. A non-gaussian model for time series with pulses.J. Am. Statist. Assoc. 84:354–359 (1989).
Part of this work was presented in abstract form at the “Symposium on Variability in Pharmacokinetics and Drug Response,” in Gothenburg (Sweden), October 3–5, 1988.
P. Francheteau holds a research sponsorship from the Centre de Recherche Préclinique of the Laboratoires Sandoz, Rueil-Malmaison, France.
About this article
Cite this article
Francheteau, P., Steimer, JL., Dubray, C. et al. Mathematical model forin vivo pharmacodynamics integrating fluctuation of the response: Application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203–922. Journal of Pharmacokinetics and Biopharmaceutics 19, 287–309 (1991). https://doi.org/10.1007/BF03036252
- pharmacokinetic-pharmacodynamic model
- circadian variation
- dopaminomimetic drug
- DCN 203–922
- spline smoothing